PL1684770T3 - Oligo-beta-(1,3)-glukan i przeciwrakowe przeciwciała monoklonalne - Google Patents

Oligo-beta-(1,3)-glukan i przeciwrakowe przeciwciała monoklonalne

Info

Publication number: PL1684770T3
Authority: PL; Poland
Prior art keywords: glucan; beta; oligo; monoclonal antibodies; antibodies against
Prior art date: 2003-10-30

Application number

PL04791108T

Other languages

English (en)

Inventor

Jean-Claude Yvin

Edouard Panak

Vaclav Vetvicka

Original Assignee

Laboratoires Goemar S A

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2003-10-30

Filing date

2004-10-29

Publication date

2009-12-31

2004-10-29 Application filed by Laboratoires Goemar S A filed Critical Laboratoires Goemar S A

2009-12-31 Publication of PL1684770T3 publication Critical patent/PL1684770T3/pl

Links

229920002498 Beta-glucan Polymers 0.000 title abstract 3
206010028980 Neoplasm Diseases 0.000 title abstract 3
201000011510 cancer Diseases 0.000 title abstract 3
DBTMGCOVALSLOR-DEVYUCJPSA-N (2s,3r,4s,5r,6r)-4-[(2s,3r,4s,5r,6r)-3,5-dihydroxy-6-(hydroxymethyl)-4-[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-6-(hydroxymethyl)oxane-2,3,5-triol Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](CO)O[C@H](O)[C@@H]2O)O)O[C@H](CO)[C@H]1O DBTMGCOVALSLOR-DEVYUCJPSA-N 0.000 abstract 1
229920001543 Laminarin Polymers 0.000 abstract 1
239000005717 Laminarin Substances 0.000 abstract 1
241001465754 Metazoa Species 0.000 abstract 1
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 abstract 1
239000008280 blood Substances 0.000 abstract 1
239000003937 drug carrier Substances 0.000 abstract 1
239000000203 mixture Substances 0.000 abstract 1
230000001225 therapeutic effect Effects 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
Molecular Biology (AREA)
Bioinformatics & Cheminformatics (AREA)
Immunology (AREA)
Microbiology (AREA)
Mycology (AREA)
Oncology (AREA)
Biomedical Technology (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Polysaccharides And Polysaccharide Derivatives (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Peptides Or Proteins (AREA)

PL04791108T 2003-10-30 2004-10-29 Oligo-beta-(1,3)-glukan i przeciwrakowe przeciwciała monoklonalne PL1684770T3 (pl)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US10/698,034 US7070778B2 (en)	2003-10-30	2003-10-30	Therapeutical combination against cancer
EP04791108A EP1684770B1 (en)	2003-10-30	2004-10-29	Oligo-beta-(1,3)-glucan and monoclonal antibodies against cancer
PCT/EP2004/013119 WO2005049044A1 (en)	2003-10-30	2004-10-29	Oligo-beta-(1, 3) -glucan and monoclonal antibodies against cancer

Publications (1)

Publication Number	Publication Date
PL1684770T3 true PL1684770T3 (pl)	2009-12-31

Family

ID=34550517

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PL04791108T PL1684770T3 (pl)	2003-10-30	2004-10-29	Oligo-beta-(1,3)-glukan i przeciwrakowe przeciwciała monoklonalne

Country Status (11)

Country	Link
US (1)	US7070778B2 (pl)
EP (1)	EP1684770B1 (pl)
AT (1)	ATE435020T1 (pl)
CY (1)	CY1109817T1 (pl)
DE (1)	DE602004021842D1 (pl)
DK (1)	DK1684770T3 (pl)
ES (1)	ES2328822T3 (pl)
PL (1)	PL1684770T3 (pl)
PT (1)	PT1684770E (pl)
SI (1)	SI1684770T1 (pl)
WO (1)	WO2005049044A1 (pl)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7906492B2 (en) *	2001-01-16	2011-03-15	Sloan-Kettering Institute For Cancer Research	Therapy-enhancing glucan
US7507724B2 (en) *	2001-01-16	2009-03-24	Sloan-Kettering Institute For Cancer Research	Therapy-enhancing glucan
US8323644B2 (en) *	2006-01-17	2012-12-04	Sloan-Kettering Institute For Cancer Research	Therapy-enhancing glucan
US20090053221A1 (en) *	2006-01-17	2009-02-26	Cheung Nai-Kong V	Immune response enhancing glucan
WO2007146417A2 (en) *	2006-06-15	2007-12-21	Biopolymer Engineering, Inc. Dba Biothera, Inc.	Glucan compositions and methods of enhancing cr3 dependent neutrophil-mediated cytotoxicity
CN100457766C (zh) *	2006-09-26	2009-02-04	重庆邮电大学	非天然活性葡聚四糖烷基苷类化合物及其制备方法和应用
FR2910322B1 (fr) *	2006-12-22	2009-10-30	Mer Soc Par Actions Simplifiee	Utilisation d'oligo-b-(1,3)-glucanes modifies pour le traite traitement de maladies du systeme immunitaire, oligo-b-(1,3) glucane-(1,3)-mannose, oligo-b-(1,3)-glucane-(1,3)-mannitol et leurs derives, ...
WO2009035617A1 (en) *	2007-09-10	2009-03-19	Barofold, Inc.	High-pressure refolding of monoclonal antibody aggregates
US20110182888A1 (en) *	2008-04-08	2011-07-28	Peter Ordentlich	Administration of an Inhibitor of HDAC, an Inhibitor of HER-2, and a Selective Estrogen Receptor Modulator
CN102308800A (zh) *	2010-06-30	2012-01-11	中国科学院大连化学物理研究所	一种可德兰寡糖的应用
CN102405906B (zh) *	2011-10-28	2013-10-23	海南正业中农高科股份有限公司	一种用于抗胡椒病毒病的壳寡糖组合物及其用途和方法
CN102415384B (zh) *	2011-10-28	2013-12-25	海南正业中农高科股份有限公司	壳寡糖用于调节作物生长的用途
EP2975937A1 (en)	2013-03-20	2016-01-27	Bioatlantis Limited	A non-nematicidal composition and use thereof
LT6145B (lt)	2014-04-14	2015-04-27	Uab "Biocentras"	TERAPINĖ ß-GLIUKANŲ KOMPOZICIJA, MODULIUOJANTI ŽMOGAUS IMUNINĘ SISTEMĄ IR INICIJUOJANTI VĖŽINIŲ LĄSTELIŲ ARDYMĄ
US11865135B2 (en)	2016-12-07	2024-01-09	Innate Biotherapeutics, Llc	ß-1,6-glucan therapeutic antibody conjugates
WO2018106644A1 (en) *	2016-12-07	2018-06-14	Innate Biotherapeutics, Llc	ß-1,6-GLUCAN TRASTUZUMAB ANTIBODY CONJUGATES
WO2023002252A1 (en)	2021-07-21	2023-01-26	Bioatlantis Limited	Composition comprising beta-glucans and alpha-fucans for improving gut health and animal performance and methods of making the same

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US45706A (en) *		1865-01-03		Improvement in apparatus for aerating dough
WO1998039013A1 (en)	1997-03-04	1998-09-11	Peregrine Pharmaceutical, Inc.	Composition and method for treating cancer and immunological disorders resulting in chronic conditions
FR2777281B1 (fr) *	1998-04-14	2000-06-30	Goemar Lab Sa	Procede de synthese du d-laminaribiose
FR2804684B1 (fr)	2000-02-04	2002-06-28	Goemar Lab Sa	Procede pour la preparation de derives fonctionnalises de beta-(1,3)-glucanes
US6454697B1 (en) *	2000-07-18	2002-09-24	Dai-Yuan Wang	Cardiac support device and method
US6660722B2 (en)	2001-11-30	2003-12-09	Laboratoires Goemar S.A.	Therapeutical treatments

2003
- 2003-10-30 US US10/698,034 patent/US7070778B2/en not_active Expired - Fee Related
2004
- 2004-10-29 PT PT04791108T patent/PT1684770E/pt unknown
- 2004-10-29 DE DE602004021842T patent/DE602004021842D1/de not_active Expired - Lifetime
- 2004-10-29 WO PCT/EP2004/013119 patent/WO2005049044A1/en not_active Ceased
- 2004-10-29 DK DK04791108T patent/DK1684770T3/da active
- 2004-10-29 PL PL04791108T patent/PL1684770T3/pl unknown
- 2004-10-29 EP EP04791108A patent/EP1684770B1/en not_active Expired - Lifetime
- 2004-10-29 AT AT04791108T patent/ATE435020T1/de active
- 2004-10-29 ES ES04791108T patent/ES2328822T3/es not_active Expired - Lifetime
- 2004-10-29 SI SI200431213T patent/SI1684770T1/sl unknown
2009
- 2009-09-09 CY CY20091100936T patent/CY1109817T1/el unknown

Also Published As

Publication number	Publication date
WO2005049044A1 (en)	2005-06-02
DK1684770T3 (da)	2009-11-09
EP1684770A1 (en)	2006-08-02
US7070778B2 (en)	2006-07-04
CY1109817T1 (el)	2014-09-10
ES2328822T3 (es)	2009-11-18
PT1684770E (pt)	2009-09-29
ATE435020T1 (de)	2009-07-15
SI1684770T1 (sl)	2009-12-31
DE602004021842D1 (de)	2009-08-13
EP1684770B1 (en)	2009-07-01
US20050095250A1 (en)	2005-05-05

Publication	Publication Date	Title
CY1109817T1 (el)	2014-09-10	Ολιγο-βητα-(1,3)-γλυκανη και μονοκλωνικα αντισωματα εναντιον καρκινου
MXPA05003621A (es)	2005-10-19	Metodos de tratamiento de la enfermedad de alzheimer usando anticuerpos dirigidos contra el peptido beta amiloide y composiciones de los mismos.
MY147019A (en)	2012-10-15	Anti-alpha v beta 6 antibodies
GB2368796A (en)	2002-05-15	Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies
LU91928I2 (fr)	2012-03-09	Ipilimumab et ses dérivés pharmaceutiquement acceptables (YERVOY®)
ZA200609407B (en)	2008-07-30	Monoclonal antibodies to hepatocyte growth factor
MY145042A (en)	2011-12-15	Humanized monoclonal antibodies to hepatocyte growth factor
PL397846A1 (pl)	2012-05-21	Leczenie zaburzeń związanych z TNFα
EP1470146B8 (en)	2007-09-12	Antibodies against the muc18 antigen
DE60236646D1 (de)	2010-07-22	Anti-VEGF-2 Antikörper
ATE519501T1 (de)	2011-08-15	Rekombinanter anti-cd40 antikörper und dessen anwendungen
MXPA02000119A (es)	2003-07-21	Elementos mezcladores estaticos apilados.
WO2003016467A3 (en)	2004-01-15	Use of antibodies having high affinity for soluble ass to treat conditions and diseases related to ass
WO2003075855A3 (en)	2006-03-23	Antibodies against cancer antigen tmeff2 and uses thereof
ATE355288T1 (de)	2006-03-15	Verbindungen und therapeutische methoden
ATE373016T1 (de)	2007-09-15	Induktion von immunologischer toleranz gegen einen therapeutischen antikörper durch varianten des therapeutischen antikörpers
AU2003244762A1 (en)	2003-12-19	Methods and compositions for intravesical therapy of bladder cancer
EP2107071A3 (en)	2009-12-30	Anti-EpCAM immunoglobulins
WO2005027936A3 (en)	2005-07-28	Pharmaceutical compositions and therapeutical treatment with oligo-beta-(1, 3)-glucans
DE69426767D1 (de)	2001-04-05	Anti idiotypische Antikörper gegen Gonococcen und diese verwendende Verfahren und Zusammensetzungen.
TR200103432T2 (tr)	2002-10-21	Engelleyici monoklonal VLA-1 antikoru ve enflamasyonlu hastalıkların tedavisinde kullanımı.
WO2002100343A3 (en)	2005-03-17	N-terminally truncated galectin-3 and antibodies for treating cancer
WO2003097082A3 (en)	2004-12-09	Treatment of crohn's disease or psoriasis using anti-inteferon gamma antibodies
AU2013204147B2 (en)	2015-09-03	Treatment of TNFalpha related disorders
MXNL05000001A (es)	2006-07-03	Conjugados de carbohidrato-somatostina-14.